DOCSLIB.ORG

Determining Beta-Lactam Resistance Among Gram-Negative Isolates in the Phoenix™ Automated Microbiology System. T

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Determining Beta-Lactam Resistance Among Gram-Negative Isolates in the Phoenix™ Automated Microbiology System. T As presented at the 10th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 2000. Determining Beta-Lactam Resistance among Gram-Negative Isolates in the Phoenix™ Automated Microbiology System. T. WILES, J. HEJNA, M. GOSNELL, C. YU AND V. KENNEDY BD Biosciences • 7 Loveton Circle • Sparks, MD, USA 21152 ABSTRACT OBJECTIVES: To determine beta-lactam resistance among gram-negative isolates using the Phoenix™ Automated Microbiology System that is currently under development. METHODS: Phoenix™ susceptibility test results of 210 gram-negative strains that included a challenge set of 110 isolates with known resistance mechanisms and 100 recently acquired clinical isolates were compared to results obtained with a NCCLS recommended Standard Broth Microdilution (SBM) method. Doubling concentrations of ampicillin, amoxicillin, ticarcillin, piperacillin, imipenem and meropenem were tested in both Phoenix™ and SBM. RESULTS: The overall essential agreement ranged from 91 to 98%. Categorical agreement was from 95 to 100%. OBJECTIVES One very major error was observed with ticarcillin (1%) The beta-lactams are the most utilized and diverse class of all antimicrobial agents. The action of beta-lactams is to inhibit and one with piperacillin (1.3%). No other very major D-alanyl-D-alanine transpeptidase activity by forming stable errors were observed. The major error rates were as follows: esters with the opened lactam ring attached to the –OH group of the enzyme target site. Resistance to beta-lactams in gram- ampicillin (2.1%), amoxicillin (2.5%), ticarcillin (4.0%), negative organisms is often mediated by reduced outer piperacillin (3.1%), imipenem (0.6%) and meropenem (0%). membrane permeability or the production of beta-lactamases. The emergence of antimicrobial resistance among gram-negative CONCLUSIONS: The observations in this study indicate an bacteria, especially high-level resistance to more extended acceptable level of performance in the detection of gram- spectrum beta-lactams, has been reported. The reliable and rapid detection of gram-negative bacterial resistance to beta-lactams is negative resistance to the beta-lactam antibiotics. paramount to a successful therapeutic outcome. The Phoenix™ Automated Microbiology System (BD Biosciences, Sparks, MD, USA) (product currently under Very Major Major development) is intended for the rapid and automated Antibiotic Name n EA % CA % % (n) % (n) identification and susceptibility testing of clinically relevant Aminopenicillins Ampicillin 159 98 97 0 (0) 2.1 (1) bacteria. The emergence of antimicrobial resistance among Amoxicillin 170 95 97 0 (0) 2.5 (1) gram-negative bacteria, especially in species that are frequently Carboxypenicillin isolated from clinical specimens, has placed the emphasis on the Ticarcillin 181 91 95 1.0 (1) 4.0 (3) speed and reliability of automated systems. In the past two Acylureidopenicillin decades, laboratory automation in identification and Piperacillin 184 95 96 1.3 (1) 3.1 (3) susceptibility testing has become more acceptable and allows Carbapenems clinical laboratories to report results with a high degree Imipenem 192 92 99 0 (0) 0.6 (1) of consistency. Meropenem 190 98 100 0 (0) 0 (0) This evaluation investigated the performance of the Phoenix™ System in detecting recognized beta-lactam resistance mechanisms in gram-negative bacteria. The overall performance was based on the accuracy of susceptibility test results generated by the Phoenix™ System as compared to results using the NCCLS recommended test procedures. METHODS BACTERIAL STRAINS. A total of 110 stock isolates with instructions and incubated for 16–20 h at 35°C in ambient air. known resistance mechanisms and 100 recently acquired fresh Panels were read on the PASCO reader. The NCCLS breakpoints clinical isolates were included in this evaluation. These test were used for categorical interpretation (M100-S10). strains were obtained from the Centers for Disease Control and PHOENIX.™ Phoenix™ panels were manufactured by BD Prevention (Atlanta, GA), La Société Française de Microbiologie Biosciences. Standardized inoculum for each strain was diluted (French National Reference Center Collection, Paris, France), the in Phoenix™ AST Broth, to which one drop of the AST Indicator BD Biosciences (BDB) internal culture collection and fresh clinical had already been added. The final inoculum density was isolates (less than 7 days old from the primary isolation). The approximately 5x105 cfu/ml. The inoculum was poured into the identification of the isolates are listed in Table 1. The characterized Phoenix™ Panel. A panel closure was secured in place and the resistance mechanisms tested in the study are listed in Table 2. inoculated panels were placed into the Phoenix™ instrument. STANDARD BROTH MICRODILUTION (SBM). Frozen Each strain was prepared in duplicate and the panels were microbroth dilution panels manufactured by PASCO (PASCO placed in the Phoenix™ instrument. MICs and categorical Laboratories, BD Biosciences, Sparks, MD) were used as the interpretations (based on the NCCLS breakpoints) were reference. SBM panels were manufactured in doubling dilutions generated by the Phoenix™ instrument. The Phoenix™ System per NCCLS guidelines. The following beta-lactams were tested MICs and categorical interpretations were compared to the in the study: ampicillin (0.5–32 µg/ml), amoxicillin (0.5–32 µg/ml), values obtained from the reference SBM. ticarcillin (1–128 µg/ml), piperacillin (0.5–128 µg/ml), imipenem (0.25–16 µg/ml) and meropenem (0.25–16 mg/ml). All panels were stored at –70°C till ready for use. SBM panels Table 2. ™ were tested in parallel with the Phoenix panels using the same List of Genotypes/Phenotypes Tested inoculum preparation. Panels were inoculated per manufacturer’s Genotype/Phenotype n SHV 1 1 SHV 2 1 Table 1. Species Tested SHV 4 2 Species Total SHV 5 3 Acinetobacter baumannii 4 SHV 6 1 Acinetobacter lwoffii 5 TEM 1 2 Burkholderia cepacia 1 TEM 2 1 Citrobacter amalonaticus 1 TEM 3 2 Citrobacter farmeri 1 TEM 5 2 Citrobacter freundii 2 TEM 6 1 Citrobacter koseri 6 TEM 8 2 Edwardsiella tarda 1 TEM 9 2 Enterobacter aerogenes 4 TEM 10 1 Enterobacter asburiae 1 TEM 11 1 Enterobacter cloacae 5 TEM 12 1 Escherichia coli 68 TEM 24 1 Hafnia alvei 2 TEM 26 1 Klebsiella oxytoca 6 SHV 1, TEM 1 1 Klebsiella pneumoniae ssp ozaenae 1 ANT(2’), OXA 3 1 Klebsiella pneumoniae ssp pneumoniae 27 deletion of OmpC, d OmpF 1 Kluyvera ascorbata 1 ESBL/OSBL 1 Morganella morganii 3 IRT 2, TEM 30 1 Pantoea agglomerans 3 IRT 5, TEM 33 1 Proteus mirabilis 9 IRT 7, TEM 36 1 Proteus vulgaris 3 AmpC 3 Providencia alcalifaciens 2 AmpC derepressed mutants 1 Providencia rettgeri 2 AmpC hyperproducer 1 Providencia stuartii 2 SME 1 1 Pseudomonas aeruginosa 17 TLS 1 Salmonella species 2 basal beta-lactamase 1 Serratia liquefaciens 3 b-lac derepressed mutant 1 Serratia marcescens 3 K1 hyperproduction 3 Serratia odorifera 21 CTX 1 1 Serratia plymuthica 2 OXA 1 1 Shigella boydii 1 OXA 2 1 Shigella flexneri 1 PSE 1 1 Shigella sonne 2 PSE 2 1 Stenotrophomonas maltophilia 4 NMC A 1 Vibrio cholerae 1 Unidentified 160 RESULTS AND DISCUSSIONS A range of 159 to 192 strains yielded valid results for the antibiotics tested (Table 4). In the study, the previously characterized Extended-spectrum beta-lactamase (ESBL) producing E. coli (13 strains) and Klebsiella species (18 strains) were confirmed using the NCCLS ESBL confirmatory test (M100-S10). The essential and categorical agreements are listed in Table 3 and 4. The average time to results is listed in Table 5. The strain showing a very major error (VME) with piperacillin was previously detected as a Pseudomonas aeruginosa strain resistant to cefepime. However, the strain showing a VME with ticarcillin was a Proteus vulgaris strain with no known resistance mechanism. Table 5. Average Time to Result Table 3. Essential Agreement of Phoenix™ System with Reference Method for Beta-Lactams Tested Distribution of Reference MIC Phoenix™ Average Time Species to Result (hour) Drug <=0.25 <=0.5 <=1 <0.5 =1 =2 =4 =8 =16 =32 =64 =128 >16 >32 >128 EA % Achromobacter 15.1 Ampicillin 41 8209736 102 98 Acinetobacter 7.0 Amoxicillin 6 2 11 20 4 2 4 121 95 Burkholderia 11.9 Ticarcillin 21 21 16 385913 8591 Citrobacter 8.2 Piperacillin 15 13 29 13 13 13 7 5 7 69 95 Edwardsiella 8.2 Imipenem 100 30 27 13 10 2 1 9 92 Enterobacter 7.5 Meropenem 156 10 84221 7 98 Escherichia 7.4 1. Number of strains with the indicated reference MIC. Hafnia 8.3 Klebsiella 7.1 Kluyvera 9.7 Morganella 7.7 Table 4. Categorical Agreement of Phoenix™ System with Reference Method Pantoea 9.5 Proteus 7.9 Very Major Major Total Reference N CA Errors Errors Providencia 8.2 Class Name N S I R % N % N % Pseudomonas 13.5 alpha-aminopenicillin Ampicillin 159 47 3 109 97 0 0.0 1 2.1 Salmonella 8.0 alpha-aminopenicillin Amoxicillin 170 40 5 125 97 0 0.0 1 2.5 Serratia 8.3 alpha-carboxypenicillin Ticarcillin 181 75 8 98 95 1 1.0 3 4.0 Shigella 7.2 N-acylureidopenicillin Piperacillin 184 98 10 76 96 1 1.3 3 3.1 Stenotrophomonas 8.9 Carbapenem Imipenem 192 137 6 39 99 0 0.0 1 0.6 Vibrio 8.4 Carbapenem Meropenem 190 134 16 42 100 0 0.0 0 0.0 Average 8.9 CONCLUSION I The overall essential agreement ranged from 91 to 98% for the beta-lactams tested. The average time to results of these beta-lactams ranged from 7 to 15 hours depending on the genus tested. I The categorical agreement ranged from 95 to 100%. There was only one very major error observed with ticarcillin (1%) and one with piperacillin (1.3%). No other very major errors were observed for the beta-lactams tested.
Load more

Recommended publications
  • Simultaneous Determination of Amoxicillin and Clavulanic Acid in Pharmaceutical Preparations by Capillary Zone Electrophoresis
    Brazilian Journal of Pharmaceutical Sciences vol. 52, n. 2, apr./jun., 2016 Article http://dx.doi.org/10.1590/S1984-82502016000200006 Simultaneous determination of amoxicillin and clavulanic acid in pharmaceutical preparations by capillary zone electrophoresis Gabriel Hancu1,*, Anamaria Neacşu1, Lajos Attila Papp1, Adriana Ciurba2 1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Medicine and Pharmacy, TîrguMureş, Romania, 2Department of PharmaceuticalTechnology, Faculty of Pharmacy, University of Medicine and Pharmacy, Tîrgu Mureş, Romania Clavulanic acid enhances the antibacterial spectrum of amoxicillin by rendering most β-lactamase producing isolates susceptible to the drug. A fast, simple and efficient capillary electrophoresis method was developed for the simultaneous determination of amoxicillin and clavulanic acid from complex mixtures. Using a 25 mM sodium tetraborate as background electrolyte at a pH of 9.30, + 25 kV applied voltage, 25 °C system temperature, UV determination at 230 nm; we succeeded in simultaneous separation of amoxicillin and clavulanic acid in approximately 2 minutes. The analytical performance of the method was evaluated in terms of reproducibility, precision, accuracy, and linearity. The optimized analytical method was applied for the determination of the two analytes from combined commercial pharmaceutical preparations. This CE method is fast, inexpensive, efficient, and environmentally friendly when compared with the more frequently used high performance liquid chromatography methods described in the literature. Uniterms: Amoxicillin/determination. Clavulanic acid/determination. Capillary electrophoresis/ quantitative analysis. Antibacterials/quantitative analysis. O ácido clavulânico acentua o espectro antibacteriano de amoxicilina, tornando a maioria dos isolados produtores de β-lactamase sensíveis ao fármaco. Desenvolveu-se um método rápido, simples e eficiente de electroforese capilar (EC) para a determinação simultânea de amoxicilina e de ácido clavulânico a partir de misturas complexas.
    [Show full text]
  • Antibiotic Use for Sepsis in Neonates and Children: 2016 Evidence Update
    Antibiotic Use for Sepsis in Neonates and Children: 2016 Evidence Update Aline Fuchsa, Julia Bielickia,b, Shrey Mathurb, Mike Sharlandb, Johannes N. Van Den Ankera,c a Paediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel, Basel, Switzerland b Paediatric Infectious Disease Research Group, Institute for Infection and Immunity, St George's University of London, London, United Kingdom c Division of Clinical Pharmacology, Children’s National Health System, Washington, DC, USA WHO-Reviews 1 TABLE OF CONTENTS 1. INTRODUCTION ............................................................................................................................... 3 1.1. Aims ......................................................................................................................................... 3 1.2. Background ............................................................................................................................. 3 1.2.1. Definition and diagnosis ................................................................................................. 3 Neonatal Sepsis ............................................................................................................................... 3 Paediatric Sepsis ............................................................................................................................. 4 Community versus hospital acquired sepsis .................................................................................. 5 1.2.2. Microbiology ..................................................................................................................
    [Show full text]
  • Comparative Activity of Newer Antibiotics Against Gram-Negative Bacilli
    CONTRIBUTION • Comparative activity of newer antibiotics against gram-negative bacilli CYNTHIA C. KNAPP, MS AND JOHN A. WASHINGTON, MD • The in vitro activities of cefoperazone, cefotaxime, ceftriaxone, ceftazidime, azlocillin, mezlocillin, piperacillin, ticarcillin/clavulanate, aztreonam, imipenem, and ciprofloxacin were concurrently deter- mined against over 1,000 isolates of gram-negative bacilli from clinical specimens of patients at the Cleve- land Clinic. Cephalosporins, penicillins, and aztreonam were active against species of Enterobacteriaceae other than Citrobacter freundii, Enterobacter aerogenes, and Enterobacter cloacae. Ceftazidime was the most active cephalosporin against Pseudomonas aeruginosa. Against the Enterobacteriaceae, the rank order of activity of penicillins was ticarcillin/clavulanate > piperacillin > mezlocillin > azlocillin. Against P. aer- uginosa, the rank order of activity of penicillins was piperacillin > ticarcillin/clavulanate > azlocillin > mezlocillin. Aztreonam was less active v P. aeruginosa than ceftazidime, cefoperazone, or piperacillin. The most active antimicrobials against all isolates tested were imipenem and ciprofloxacin. • INDEX TERMS: ANTIBIOTICS, LACTAM; GRAM-NEGATIVE BACTERIA • CLEVE CLIN J MED 1989; 56:161-166 HE RECENT introduction of ciprofloxacin for and penicillins, as well as the monobactam, aztreonam, clinical use follows closely a period of active re- and the carbapenem, imipenem.1-3 search in and development of expanded spec- We compared the susceptibility of more than 1,000 trum p-lactam antibiotics, including cephalo- clinical bacterial isolates to four expanded spectrum Tsporins, penicillins, monobactams, and carbapenems. cephalosporins (cefoperazone, cefotaxime, ceftriaxone, Although numerous published studies compare the ac- and ceftazidime), four expanded spectrum penicillins tivity of ciprofloxacin with other quinolones, only a (azlocillin, mezlocillin, piperacillin, and ticarcil- limited number of studies compare the activity of ci- lin/clavulanate), aztreonam, imipenem, and ciproflox- acin.
    [Show full text]
  • Treatment of Extended-Spectrum Β-Lactamase
    F1000Research 2018, 7(F1000 Faculty Rev):1347 Last updated: 17 JUL 2019 REVIEW Treatment of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBLs) infections: what have we learned until now? [version 1; peer review: 2 approved] Zoi Dorothea Pana1, Theoklis Zaoutis 2 1Infectious Diseases Department, 3rd Department of Pediatrics, Hippokration General Hospital Aristotle University, Thessaloniki, Greece 2Infectious Diseases Department, The Children’s Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA First published: 29 Aug 2018, 7(F1000 Faculty Rev):1347 ( Open Peer Review v1 https://doi.org/10.12688/f1000research.14822.1) Latest published: 29 Aug 2018, 7(F1000 Faculty Rev):1347 ( https://doi.org/10.12688/f1000research.14822.1) Reviewer Status Abstract Invited Reviewers The spread of extended-spectrum β-lactamase (ESBL)-producing 1 2 Enterobacteriaceae (ESBL-PE) has dramatically increased worldwide, and this “evolving crisis” is currently regarded as one of the most important version 1 public health threats. The growing problem of ESBL-PE antimicrobial published resistance seems to have a dual face between “Scylla and Charybdis”: on 29 Aug 2018 one hand the potential for rapid spread and dissemination of resistance mechanisms and on the other hand the injudicious overuse of antimicrobial agents and the inadequate infection control measures, especially in the F1000 Faculty Reviews are written by members of health-care setting. Given the World Health Organization’s warning against the prestigious F1000 Faculty. They are a “post antibiotic era”, health-care providers are at a critical standpoint to commissioned and are peer reviewed before find a “balance” between safe and effective ESBL-PE treatment and publication to ensure that the final, published version avoidance of inducing further resistance mechanisms.
    [Show full text]
  • Clinical Pharmacology of Ampicillin in Infants and Children
    Central Journal of Drug Design and Research Bringing Excellence in Open Access Review Article *Corresponding author Gian Maria Pacifici,Associate professorof Pharmacology,via Sant’Andrea 32,56127 Pisa,Italy. Clinical Pharmacology of Email: [email protected] Submitted: 19 April 2021 Accepted: 25 April 2021 Ampicillin in Infants and Published: 27 April 2021 ISSN: 2379-089X Children Copyright © 2021 Pacifici GM Gian Maria Pacifici* OPEN ACCESS Associate professorof Pharmacology, Italy Keywords Abstract • Ampicillin • Dosing Ampicillin is an aminopenicillin and is more active than penicillin G. Ampicillin is destroyed by β-lactamase • Treatment and is co-formulated with sulbactam an inhibitor of β-lactamase. Ampicillin is bactericidal and it is active • Trials against meningococci, Listeria monocytogenes, enterococci, and the co-administration with sulbactam markedly • Placental-transfer expands the spectrum of activity against Haemophilus influenzae, Escherichia coli, Proteus, and Bacillus fragilis. • Breast-milk Ampicillin may be administered intravenously and orally and the intravenous dose is 50 mg twice-daily and • Meningitis thrice-daily in preterm and term infants, respectively. The oral dose in children ranges from 125 to 500 mg 4 times-daily and increases with the chid age. Ampicillin has been found efficacy and safe in infants and children but may cause adverse-effects. In infants, the ampicillin elimination half-life ranges between 2.4 to 5.0 hours and decreases with infant maturation and in children it is about 0.8 hours. Ampicillin interacts with drugs, the treatment and the trials with ampicillin have been extensively studied in infants and children. This antibiotic freely crosses the human placenta but poorly migrates into the breast-milk.
    [Show full text]
  • Evaluation of the Coverage of 3 Antibiotic Regimens for Neonatal Sepsis in the Hospital Setting Across Asian Countries
    Original Investigation | Global Health Evaluation of the Coverage of 3 Antibiotic Regimens for Neonatal Sepsis in the Hospital Setting Across Asian Countries Julia A. Bielicki, MD; Mike Sharland, MD; Paul T. Heath, FRCPCH; A. Sarah Walker, PhD; Ramesh Agarwal, MD; Paul Turner, PhD; David A. Cromwell, PhD Abstract Key Points Question What is the antibiotic IMPORTANCE High levels of antimicrobial resistance in neonatal bloodstream isolates are being coverage offered by empirical neonatal reported globally, including in Asia. Local hospital antibiogram data may include too few isolates to sepsis treatment with aminopenicillin- meaningfully examine the expected coverage of antibiotic regimens. gentamicin, third-generation cephalosporins (cefotaxime or OBJECTIVE To assess the coverage offered by 3 antibiotic regimens for empirical treatment of ceftriaxone), and meropenem in Asian neonatal sepsis in Asian countries. countries? DESIGN, SETTING, AND PARTICIPANTS A decision analytical model was used to estimate coverage Findings In this decision analytical of 3 prespecified antibiotic regimens according to a weighted-incidence syndromic combination model based on a decision tree, 8376 antibiogram. Relevant data to parameterize the models were identified from a systematic search of isolates from 10 countries were used to Ovid MEDLINE and Embase. Data from Asian countries published from 2014 onward were of interest. estimate coverage. Meropenem Only data on blood culture isolates from neonates with sepsis, bloodstream infection, or bacteremia generally had the highest coverage reported from the relevant setting were included. Data analysis was performed from April 2019 to (from 64.0% in India to 90.6% in July 2019. Cambodia) followed by aminopenicillin- gentamicin (from 35.9% in Indonesia to EXPOSURES The prespecified regimens of interest were aminopenicillin-gentamicin, third- 81.0% in Laos) and cefotaxime or generation cephalosporins (cefotaxime or ceftriaxone), and meropenem.
    [Show full text]
  • Chemistry Classification Pharmacokinetics Clinical Uses And
    Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research, 2014, 6(11):28-58 ISSN : 0975-7384 Review Article CODEN(USA) : JCPRC5 Chemistry, classification, pharmacokinetics, clinical uses and analysis of beta lactam antibiotics: A review Mamdouh S. Masoud a, Alaa E. Ali b* and Nessma M. Nasr c aChemistry Department, Faculty of Science, Alexandria University, Alexandria, Egypt bChemistry Department, Faculty of Science, Damanhour University, Damanhour, Egypt cStudents’ Hospital, Alexandria University, Alexandria, Egypt _____________________________________________________________________________________________ ABSTRACT This review attempts to pinpoint the importance of betalactam antibiotics, which encompass penicillins, cephalosporins, cephamycins, carbapenems and monobactams from its chemistry, classification, pharmacokinetics, clinical uses and analysis. β- lactam antibiotics have been used for treatment of bacterial infections. Most antibacterials are chemically semisynthetic modifications of various natural compounds and classified on the basis of chemical /biosynthetic origin into natural, semisynthetic, and synthetic. Also, this classification system is based on biological activity; that antibacterials are divided into two broad groups according to their biological effect on microorganisms, bactericidal agents kill bacteria, and bacteriostatic agents slow down bacterial growth. Keywords: Beta lactam Antibiotics, Classification, Pharmacokinetics, Clinical uses, Analysis. _____________________________________________________________________________________________
    [Show full text]
  • Reflection Paper on the Use of Aminopenicillins and Their Beta
    1 13 September 2018 2 EMA/CVMP/AWP/842786/2015 3 Committee for Medicinal Products for Veterinary Use (CVMP) 4 Reflection paper on the use of aminopenicillins and their 5 beta-lactamase inhibitor combinations in animals in the 6 European Union: development of resistance and impact 7 on human and animal health 8 Draft Draft agreed by Antimicrobials Working Party (AWP) 9 July 2018 Adopted by CVMP for release for consultation 13 September 2018 Start of public consultation 21 September 2018 End of consultation (deadline for comments) 21 December 2018 9 Comments should be provided using this template. The completed comments form should be sent to [email protected] 10 Keywords aminopenicillins, antimicrobial resistance 11 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 12 13 Table of contents 14 Executive summary ..................................................................................... 4 15 CVMP Recommendations for action ............................................................. 6 16 1. Background ............................................................................................. 7 17 2. General drug characteristics .................................................................... 8 18 2.1. Structure and mechanism of action ......................................................................
    [Show full text]
  • FINRES-Vet 2016–2017 Finnish Veterinary Antimicrobial Resistance Monitoring and Consumption of Antimicrobial Agents
    Evira publications 5/2018 FINRES-Vet 2016–2017 Finnish Veterinary Antimicrobial Resistance Monitoring and Consumption of Antimicrobial Agents Evira publications 5/2018 FINRES-Vet 2016–2017 Finnish Veterinary Antimicrobial Resistance Monitoring and Consumption of Antimicrobial Agents FINRES-Vet 2016–2017 - Finnish Veterinary Antimicrobial Resistance Monitoring and Consumption of Antimicrobial Agents Authors and institutions participating in making the FINRES-Vet report Finnish Food Safety Authority Evira Suvi Nykäsenoja, Tarja Pohjanvirta, Mia Biström, Mirja Raunio-Saarnisto, Liisa Kaartinen, Henriette Helin-Soilevaara, Katariina Pekkanen Finnish Medicines Agency FIMEA Katariina Kivilahti-Mäntylä, Martti Nevalainen Faculty of Veterinary Medicine, University of Helsinki Merja Rantala, Thomas Grönthal Acknowledgements The coordinators of the FINRES-Vet programme wish to thank the meat inspection personnel of Evira and slaughterhouses for collecting the samples from animals at slaughter. Also, the personnel of Evira who has participated in the meat sampling at retail are acknowledged. Any use of data from FINRES-Vet 2016–2017 should include a specific reference to this report. Suggested citation: FINRES-Vet 2016-2017, Finnish Veterinary Antimicrobial Resistance Monitoring and Consumption of Antimicrobial Agents, Finnish Food Safety Authority Evira, Helsinki, Finland, ISSN 1797-299X, ISBN 978-952-225-173-2 (pdf). This report is available at www.evira.fi FINRES-Vet 2016–2017 - Finnish Veterinary Antimicrobial Resistance Monitoring and Consumption
    [Show full text]
  • ARCH-Vet Anresis.Ch
    Usage of Antibiotics and Occurrence of Antibiotic Resistance in Bacteria from Humans and Animals in Switzerland Joint report 2013 ARCH-Vet anresis.ch Publishing details © Federal Office of Public Health FOPH Published by: Federal Office of Public Health FOPH Publication date: November 2015 Editors: Federal Office of Public Health FOPH, Division Communicable Diseases. Elisabetta Peduzzi, Judith Klomp, Virginie Masserey Design and layout: diff. Marke & Kommunikation GmbH, Bern FOPH publication number: 2015-OEG-17 Source: SFBL, Distribution of Publications, CH-3003 Bern www.bundespublikationen.admin.ch Order number: 316.402.eng Internet: www.bag.admin.ch/star www.blv.admin.ch/gesundheit_tiere/04661/04666 Table of contents 1 Foreword 4 Vorwort 5 Avant-propos 6 Prefazione 7 2 Summary 10 Zusammenfassung 12 Synthèse 14 Sintesi 17 3 Introduction 20 3.1 Antibiotic resistance 20 3.2 About anresis.ch 20 3.3 About ARCH-Vet 21 3.4 Guidance for readers 21 4 Abbreviations 24 5 Antibacterial consumption in human medicine 26 5.1 Hospital care 26 5.2 Outpatient care 31 5.3 Discussion 32 6 Antibacterial sales in veterinary medicines 36 6.1 Total antibacterial sales for use in animals 36 6.2 Antibacterial sales – pets 37 6.3 Antibacterial sales – food producing animals 38 6.4 Discussion 40 7 Resistance in bacteria from human clinical isolates 42 7.1 Escherichia coli 42 7.2 Klebsiella pneumoniae 44 7.3 Pseudomonas aeruginosa 48 7.4 Acinetobacter spp. 49 7.5 Streptococcus pneumoniae 52 7.6 Enterococci 54 7.7 Staphylococcus aureus 55 Table of contents 1 8 Resistance in zoonotic bacteria 58 8.1 Salmonella spp.
    [Show full text]
  • Swedres-Svarm 2005
    SVARM Swedish Veterinary Antimicrobial Resistance Monitoring Preface .............................................................................................4 Summary ..........................................................................................6 Sammanfattning................................................................................7 Use of antimicrobials (SVARM 2005) .................................................8 Resistance in zoonotic bacteria ......................................................13 Salmonella ..........................................................................................................13 Campylobacter ...................................................................................................16 Resistance in indicator bacteria ......................................................18 Escherichia coli ...................................................................................................18 Enterococcus .....................................................................................................22 Resistance in animal pathogens ......................................................32 Pig ......................................................................................................................32 Cattle ..................................................................................................................33 Horse ..................................................................................................................36 Dog
    [Show full text]
  • Incidence of Pneumonia in Nursing Home Residents in Germany: Results of a Claims Data Analysis
    Epidemiology and Infection Incidence of pneumonia in nursing home residents in Germany: results of a claims cambridge.org/hyg data analysis Original Paper A. M. Fassmer, O. Spreckelsen and F. Hoffmann – Cite this article: Fassmer AM, Spreckelsen O, Department of Health Services Research, School VI Medicine and Health Sciences, Carl von Ossietzky University Hoffmann F (2018). Incidence of pneumonia in Oldenburg, Ammerländer Heerstraße 140, Oldenburg, Lower Saxony, Germany nursing home residents in Germany: results of a claims data analysis. Epidemiology and Abstract Infection 146, 1123–1129. https://doi.org/ 10.1017/S0950268818000997 Pneumonia is one of the most common infectious diseases with a high mortality, especially in the elderly population. To date, there have been only a few population-based studies dealing Received: 10 November 2017 with the incidence of pneumonia in nursing homes (NHs). We conducted a cohort study Revised: 24 February 2018 Accepted: 2 April 2018 using data from a large German statutory health insurance fund. Between 2010 and 2014, First published online: 26 April 2018 127 227 NH residents 65 years and older were analysed. For the calculation of incidences per 100 person-years (PY) and 95% confidence intervals (CIs), we assessed the first diagnosis Key words: of pneumonia during the time in NH. We compared the rates between sexes, age groups, care Claims data; elderly; Germany; incidence; nursing home; pneumonia levels, and comorbidities and we performed a multivariate Cox regression analysis. The mean age in the cohort was 84.0 years (74.6% female). A total of 19 183 incident cases led to an Author for correspondence: overall 5-year-incidence of 11.8 per 100 PY (95% CI 11.7–12.0).
    [Show full text]